We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Medical Mktg | LSE:MMG | London | Ordinary Share | GB0004150685 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 3.75 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
RNS Number : 8143A
Medical Marketing Int'l Group PLC
07 August 2008
Notification of Major Interests in Shares
Thursday, 7 August 2008. Medical Marketing International Group plc (the "Company") (AIM:MMG) the life sciences company focused on the
development of drugs for cancer, received notification on 6 August 2008 that as at 5 August 2008 the interest of Prudential plc and certain
of its subsidiaries has increased from 10,126,407 to 12,726,407 ordinary shares of 0.2p each of the Company; this represents 19.99% of the
Company's issued share capital of 63,665,557 ordinary shares.
The Company also received notification on 6 August 2008 that as at 5 August 2008 that included within the above interest, the interest
of M&G Investments Funds 3, an Open Ended Investment Company managed by M&G investment Management Limited (a wholly owned subsidiary of
Prudential plc), has increased from 8,961,269 to 11,112,761 ordinary shares of 0.2p each of the Company; this represents 17.45% of the
Company's issued share capital of 63,665,557 ordinary shares.
Enquiries:
Medical Marketing International Group plc
Phil Cartmell, Non-executive Chairman Tel: +44 (0) 1223 477 677
Mark Burton, Chief Technical Officer
Rob Sprawson, Chief Financial Officer
FinnCap
Sam Smith/Charlie Cunningham Tel: +44 (0)20 7600 1658
Financial Dynamics
David Yates/Emma Thompson Tel: +44 (0)20 7831 3113
About MMI
Medical Marketing International Group plc ("MMI") is a life sciences company that identifies, acquires and develops world-class
compounds and technologies for the treatment of cancer. The Company manages the preclinical and early clinical development of drug
candidates before pursuing licensing partners to manage late-stage development. Please visit www.mmigroup.co.uk for further information.
Notwithstanding the inclusion on this release by MMI of a website address and/or another electronic address, MMI does not accept any
notices or any other documents or communication via its website or other electronic address. All such notices, documents or communication
shall be in hard copy format only. Accordingly the provisions of section 333 Companies Act 2006 allowing persons to communicate with MMI
electronically shall not apply to MMI.
-ends-
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUNABRWVRWRAR
1 Year Medical Mktg Chart |
1 Month Medical Mktg Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
